Director Kingsley Stuart A. of Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) executed a purchase of 940 shares of the companys common stock on March 6, 2026. The shares were acquired at $31.865 apiece, bringing the transaction value to $29,953. As of the most recent quote, INDV trades at $33.73, a modest premium to the director's purchase price.
Following this buy, Kingsley directly holds 5,582 shares of Indivior. The transaction is notable within the context of Indiviors broader stock performance - the company is valued at $4.17 billion and has recorded a 241% return over the past year.
Independent analysis from InvestingPro characterizes the stock as appearing fairly valued at current levels and assigns the company a "GREAT" financial health score. The platform also notes that a Pro Research Report is available for INDV along with more than 1,400 other U.S. equities for investors seeking deeper analytical coverage.
Operationally and financially, Indivior recently published fourth-quarter and full-year 2025 results that beat consensus expectations. The company reported earnings per share of $0.82 for the quarter versus a forecast of $0.67, representing a 22.39% earnings surprise. Quarterly revenue came in at $358 million, ahead of the $305.62 million estimate by 17.14%.
Those outperformance metrics have drawn attention among market participants. Analysts have not, as of the most recent update, indicated any changes to their ratings for Indivior. The earnings and revenue surprises are highlighted as developments that could influence future analyst assessments, though no changes have been recorded at this time.
Investors and observers remain attentive to Indiviors next strategic moves and market positioning in light of both the insider purchase and the stronger-than-expected financial results. The director's purchase, the company's recent earnings beats, and third-party valuation commentary together form the current publicly disclosed backdrop for INDV trading activity.
Contextual note - The facts above are limited to the disclosed insider transaction, company valuation and returns, InvestingPro's valuation and financial health characterization, and Indiviors published fourth-quarter and full-year 2025 results including EPS and revenue versus consensus estimates.